TORONTO, May 19 /CNW/ - Biosign Technologies Inc. (CNSX:BIO) ("Biosign" or the "Company") and Dental BioAnalytics ("BioAnalytics") today announced they have signed an exclusive Reseller Agreement to sell Biosign products in the dental market segment in Canada.
BioAnalytics is positioned to leverage its extensive understanding of, and relationships within, the dental industry to introduce Biosign's revolutionary, pulse-wave based, diagnostic products and services to dentists and their patients across Canada.
"The principals of BioAnalytics have a strong track record in bringing specialty products to market in the field of dentistry", remarked Radu Leca, Biosign's president. "Dentists have a strong relationship with their patients, and more than ever, are recognized as a key link in one's health maintenance."
The terms of the Reseller Agreement include a minimum sales volume over the term of the Agreement, including a five year growth plan achieving an estimated $10M in combined revenue. BioAnalytics will have exclusivity of distribution in the Canadian dental market for the Biosign product portfolio for the duration of the Agreement.
"Dentistry is getting more and more medicalized. Dentists and dental hygienists are playing an increasing role in diagnosing and supporting the overall health of Canadians. Patients' oral health impacts and reflects their overall health", said Joshua Gofman, President of BioAnalytics. "Periodontal disease is an inflammatory disease that, in some form, affects close to 75% of the population. It has been closely linked to cardiovascular disease, diabetes, and several other debilitating health conditions. Biosign's precise, inexpensive, and user friendly UFIT(R) technology will finally provide healthcare practitioners with a powerful patient health diagnostic and monitoring system."
About Biosign Technologies Inc.
Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information please visit www.biosign.com
About BioAnalytics Inc.
BioAnalytics Inc. (www.bio-analytics.ca) was established by Joshua Gofman, the co-founder of the highly successful oral-infection diagnostics and treatment biotechnology company OraVital (www.oravital.com), and a group of dentists and physicians for the sole purpose of marketing and deploying Biosign's advanced non-invasive health risk monitoring technology to the dental sector in Canada and other international markets.
The CNSX has neither approved nor disapproved the contents of this press release.
SOURCE Biosign Technologies Inc.
For further information: For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: (416) 218-9800 ext. 234, Email: email@example.com; Joshua Gofman, President, BioAnalytics Inc., (416) 456-2286, firstname.lastname@example.org